Breaking News Instant updates and real-time market news.

AMGN

Amgen

$168.61

-11.5 (-6.39%)

, REGN

Regeneron

$380.29

-12.3 (-3.13%)

04:55
03/19/17
03/19
04:55
03/19/17
04:55

Spargo to host an expo

66th Annual Scientific Session & Expo: ACC.17 is being held in Washington, D.C. on March 17-19.

AMGN

Amgen

$168.61

-11.5 (-6.39%)

REGN

Regeneron

$380.29

-12.3 (-3.13%)

SNY

Sanofi

$44.30

-0.27 (-0.61%)

PTLA

Portola Pharmaceuticals

$39.44

-0.76 (-1.89%)

ABT

Abbott

$45.19

0.21 (0.47%)

ABMD

Abiomed

$123.97

1.06 (0.86%)

ALIOF

Actelion

$276.30

0.55 (0.20%)

AMRN

Amarin

$3.29

0.03 (0.92%)

ARLZ

Aralez

$2.25

0.05 (2.27%)

ATRC

AtriCure

$18.96

0.09 (0.48%)

AZN

AstraZeneca

$30.69

0.17 (0.56%)

BAYRY

Bayer

$114.87

-0.375 (-0.33%)

BSX

Boston Scientific

$24.43

0.14 (0.58%)

BMY

Bristol-Myers

$56.29

-1.02 (-1.78%)

CERN

Cerner

$56.61

0.26 (0.46%)

CYTK

Cytokinetics

$12.40

-0.95 (-7.12%)

EW

Edwards Lifesciences

$94.40

1.45 (1.56%)

GILD

Gilead

$69.06

0.52 (0.76%)

KRO

Kronos Worldwide

$15.44

0.14 (0.92%)

MCK

McKesson

$147.93

-0.9 (-0.60%)

MDT

Medtronic

$82.23

0.4 (0.49%)

PFE

Pfizer

$34.32

-0.11 (-0.32%)

STJ

Acquired by ABT

WTKWY

Wolters Kluwer

$41.30

0.41 (1.00%)

  • 20

    Mar

  • 21

    Mar

  • 23

    Mar

  • 23

    Mar

  • 24

    Mar

  • 27

    Mar

  • 29

    Mar

  • 01

    Apr

  • 05

    Apr

  • 27

    Apr

  • 07

    Jun

  • 24

    Jun

  • 26

    Jun

  • 27

    Jun

  • 19

    Jul

  • 27

    Aug

AMGN Amgen
$168.61

-11.5 (-6.39%)

03/17/17
NEED
03/17/17
NO CHANGE
Target $25
NEED
Strong Buy
Needham calls Esperion selloff on Amgen data 'counter-intuitive'
Needham analyst Chad Messer believes the selloff in shares of Esperion Therapeutics (ESPR) based on Amgen's (AMGN) Repatha's data is "counter-intuitive." The fact that there was a statistically significant benefit confirms that LDL reductions prevent heart attacks and strokes, Messer tells investors in a research note. Bempedoic acid will likely be priced more in line with other oral cholesterol therapies, which makes the value debate for PCSK9 drugs a positive for Esperion, not a negative, the analyst contends. The analyst keeps a Buy rating on Esperion with a $25 price target.
03/17/17
OPCO
03/17/17
NO CHANGE
OPCO
Outperform
Amgen oversold on cholesterol data, says Oppenheimer
Oppenheimer analyst Leah Rush Cann says shares of Amgen are oversold after the FOURIER study of Repatha in patients with cardiovascular disease met its key endpoint. The risk reduction grew to 25% after one year on Repatha therapy, which is a "very important result," Cann tells investors in a research note. She believes the current stock price reflects little to no sales of Repatha through 2020. The analyst has an Outperform rating on Amgen, which is trading down 6% to $168.68.
03/17/17
PIPR
03/17/17
NO CHANGE
PIPR
Overweight
Amgen weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer recommends using today's weakness in shares of Amgen as a buying opportunity. The analyst believes Amgen can still turn Repatha into a $5B-plus product and he reiterates an Overweight rating on the shares.
03/17/17
JPMS
03/17/17
NO CHANGE
JPMS
Overweight
Amgen data do not justify Medicines selloff, says JPMorgan
JPMorgan analyst Jessica Fye believes today's cholesterol data from Amgen (AMGN) do not justify the downward move in shares of The Medicines Co. (MDCO). The analyst sees a "clear clinical benefit" from Amgen's Repatha, which she thinks support the likelihood of clinical success and value for Medicines' inclisiran. The analyst remains comfortable with her 70% probability of success and $1.6B peak sales forecast for inclisiran. Fye keeps an Overweight rating on Medicines and believes the 18% selloff today is overdone.
REGN Regeneron
$380.29

-12.3 (-3.13%)

03/08/17
PIPR
03/08/17
NO CHANGE
Target $446
PIPR
Overweight
Piper sees approval for Regeneron by March 29 PDUFA date
Piper Jaffray analyst Edward Tenthoff continues to expect Regeneron Pharmaceuticals will win FDA approval of Dupixent in atopic dermatitis by the March 29 action date. The lack of an FDA advisory panel and updated Phase III data at the American Academy of Dermatology meeting enhance the analyst's confidence in approval. Tenthoff sees long-term value for Dupixent with approvals in broader allergic indications and reiterates an Overweight rating on Regeneron shares with a $446 price target.
03/08/17
UBSW
03/08/17
INITIATION
Target $435
UBSW
Buy
Regeneron initiated with a Buy at UBS
UBS analyst Carter Gould initiated Regeneron with a Buy and a $435 price target.
03/16/17
OPCO
03/16/17
INITIATION
OPCO
Perform
Regeneron initiated with a Perform at Oppenheimer
Oppenheimer analyst Hartaj Singh started Regeneron with a Perform rating, saying Eylea is a significant cash generator and the company has three products at or nearing launch, but there are also near-term hurdles in terms of litigation, product launch costs and possible margin compression.
03/17/17
03/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with an Outperform at Bernstein. 2. Snap (SNAP) initiated with a Neutral at Mizuho. 3. Cantel Medical (CMD) initiated with a Market Perform at Raymond James. 4. Hilton (HLT) reinstated with an Overweight at JPMorgan. 5. Regeneron (REGN) initiated with a Perform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SNY Sanofi
$44.30

-0.27 (-0.61%)

02/09/17
02/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Viacom (VIA, VIAB) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying the company's first quarter results prove its turnaround is "real and likely to continue." The strategic plan put in place by CEO Bakish makes sense, Ryvicker tells investors in a research note. The analyst raised his price target range for the shares to $48-$50 from $38-$40. 2. Micron (MU) upgraded to Buy from Underperform at BofA/Merrill. 3. Sanofi (SNY) upgraded to Buy from Neutral at Natixis. 4. Hawaiian Holdings (HA) upgraded to Outperform from Peer Perform at Wolfe Research. 5. Baker Hughes (BHI) upgraded to Positive from Neutral at Susquehanna with analyst Charles Minervino citing the selloff in shares and its upside opportunity associated with a US spending upcycle, synergies from its joint-venture with General Electric (GE), and the growth opportunities that could develop from a partnership with a diversified global oilfield services company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/17
NTXS
02/09/17
UPGRADE
NTXS
Buy
Sanofi upgraded to Buy from Neutral at Natixis
03/07/17
LEHM
03/07/17
INITIATION
LEHM
Underweight
Sanofi initiated with an Underweight at Barclays
Barclays analyst Emmanuel Papadakis initiated Sanofi with an Underweight rating and EUR 70 price target.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
European Pharma raised to Positive from Neutral at Barclays
Barclays analyst Emmanuel Papadakis rolled out coverage of the European Pharmaceuticals space and upgraded his sector view to Positive from Neutral. The analyst has "high conviction that the recent transformational era of R&D innovation is set to continue," which he believes will allow the sector to retain pricing power. Papadakis put Overweight ratings on AstraZeneca (AZN), Roche (RHHBY) and Shire (SHPG), with Astra his top pick. The analyst put an Equal Weight rating on GlaxoSmithKline (GSK) and Underweight ratings on Sanofi (SNY), Novartis (NVS) and Novo Nordisk (NVO).
PTLA Portola Pharmaceuticals
$39.44

-0.76 (-1.89%)

02/17/17
SBSH
02/17/17
NO CHANGE
Target $39
SBSH
Buy
Portola Pharmaceuticals price target raised to $39 from $32 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $39 saying his analysis indicates that the FDA no longer requesting an advisory panel for betrixaban is good news. The analyst raised the approval probability of the drug to 85% from 75%. Priority review and no panel is tied to a 94% approval probability, substantially higher than the 67% approval probability for priority review with a panel, Nochomovitz tells investors in a research note, citing his analysis. He keeps a Buy rating on Portola.
02/24/17
OPCO
02/24/17
UPGRADE
Target $40
OPCO
Outperform
Portola Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
Oppenheimer analyst Jay Olson upgraded Portola Pharmaceuticals to Outperform saying no FDA advisory panel is a ''clear positive" for betrixaban. The analyst is also "increasingly optimistic" about growth of the Factor Xa inhibitor class. He raised his price target for Portola shares to $40 from $28.
03/01/17
WBLR
03/01/17
NO CHANGE
WBLR
Outperform
William Blair 'cautiously optimistic' on FDA approval for Portola
Following Portola Pharmaceuticals' Q4 results, William Blair analyst John Sonnier says he's "cautiously optimistic" on the potential for regulatory approval of betrixaban on June 24. The analyst believes approval would be worth $60 per share. Since the initial disclosure of the failed Phase III primary endpoint, the "evolution of the betrixaban story has been highly supportive," Sonnier tells investors in a research note. He believes the full data presentation at the International Society on Thrombosis and Haemostasis annual meeting in May and further sub-study results presented at the American Heart Association Scientific Sessions in November were "highly supportive of the overall benefit from betrixaban therapy." The analyst keeps an Outperform rating on Portola.
03/09/17
FBCO
03/09/17
NO CHANGE
Target $39
FBCO
Neutral
Portola Pharmaceuticals price target raised to $39 from $29 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Portola Pharmaceuticals to $39 from $29, given quarterly results, the recent HealthCare Royalty Partners deal and increasing probability of success for betrixaban. The analyst reiterates a Neutral rating on the shares given the strong move the stock has had and ahead of the American College of Cardiology Meeting.
ABT Abbott
$45.19

0.21 (0.47%)

03/01/17
RAJA
03/01/17
NO CHANGE
RAJA
Market Perform
Alere filing delay should not be surprise, says Raymond James
Raymond James analyst Nicholas Jansen says that while the annual filing delay is not a headline Alere (ALR) shareholders wanted to see given the company's current battle with Abbott (ABT), the revision just relates to timing, not "bad revenue," and is immaterial in totality relative to a $2.5B revenue base. Alere's annual filing was unlikely to include a full remediation of internal control weakness, so this issue, while disappointing, should not be a surprise, Jansen tells investors in a research note. He keeps a Market Perform rating on the shares. Alere in early trading is down 3%, or $1.27, to $37.03.
03/14/17
BMOC
03/14/17
DOWNGRADE
BMOC
Market Perform
Abbott downgraded to Market Perform from Outperform at BMO Capital
03/14/17
03/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Corning (GLW) downgraded to Neutral from Buy at Goldman with analyst Doug Clark citing valuation with the stock up 33% since his upgrade back in April of 2016. The analyst keeps a $29 price target for the shares. 2. Amphastar (AMPH) downgraded to Outperform from Strong Buy at Raymond James with analyst Elliot Wilbur saying he sees an increased near-term risk profile following indications from FDA that Amphastar may have to withdraw its epinephrine product. 3. Abbott (ABT) downgraded to Market Perform from Outperform at BMO Capital. 4. GGP (GGP) downgraded to Neutral from Buy at UBS with analyst Jeremy Metz saying he does not see headwinds in the sector easing in the short term and cut his price target for GGP shares to $25 from $28. 5. Harmonic (HLIT) downgraded to Hold from Buy at Drexel Hamilton. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/23/17
COWN
01/23/17
NO CHANGE
Target $48
COWN
Outperform
Abbott valuation compelling and discount may not last long, says Cowen
Cowen analyst Joshua Jennings said Abbott's valuation is currently at a compelling discount, but that may not last long. He said the Abbott/St. Jude Medical combination has given him conviction the combined company can sustain greater than 5% organic growth and 12-15% earnings growth in 2018 to 2020. Jennings reiterated his Outperform rating and $48 price target on Abbott shares.
ABMD Abiomed
$123.97

1.06 (0.86%)

12/07/16
GUGG
12/07/16
INITIATION
Target $150
GUGG
Buy
Abiomed initiated with a Buy at Guggenheim
Guggenheim analyst Christopher Pasquale initiated Abiomed with a Buy and a $150 price target.
12/07/16
12/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Micron (MU) initiated with a Buy at Citi. 2. Owens Corning (OC) initiated with a Buy at Seaport Global. 3. Abiomed (ABMD) initiated with a Buy at Guggenheim. 4. ZELTIQ (ZLTQ) initiated with a Buy at Aegis. 5. Navient (NAVI) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/06/16
GUGG
12/06/16
INITIATION
GUGG
Buy
Abiomed initiated with a Buy at Guggenheim
11/18/16
LEER
11/18/16
NO CHANGE
Target $140
LEER
Outperform
Abiomed remains on 'hyper-growth trajectory,' says Leerink
After hosting investor meetings with the company's CEO Mike Minogue, CFO Mike Tomsicek, and Director of IR Ingrid Goldberg, Leerink analyst Danielle Antalffy remains confident that Abiomed's fundamentals are intact, and the company remains on a "hyper-growth trajectory" with significant positive operating leverage. The analyst remains confident in a sustainable long-term "strong" double-digit growth trajectory built on a market-leading product, a large and still-expanding salesforce, and a "strong" foundation of clinical evidence. She reiterates an Outperform rating and $140 price target on the shares.
ALIOF Actelion
$276.30

0.55 (0.20%)

03/08/17
JPMS
03/08/17
UPGRADE
JPMS
Overweight
Actelion upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded Actelion (ALIOF) to Overweight citing a "high confidence" that the Johnson & Johnson (JNJ) buyout will complete. The analyst sees 7% potential return by mid-2017.
01/26/17
01/26/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cognex (CGNX) initiated with a Neutral at JPMorgan. 2. Realogy (RLGY) initiated with a Hold at Deutsche Bank. 3. EQT Midstream Partners (EQM) ande EQT GP (EQGP) were initiated with a Buy at Janney Capital. 4. Williams (WMB) was assumed with an Outperform at Credit Suisse, while Williams Partners (WPZ) was assumed with a Neutral. 5. Actelion (ALIOF) reinstated with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/26/17
WELS
01/26/17
DOWNGRADE
WELS
Market Perform
Johnson & Johnson downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen downgraded Johnson & Johnson (JNJ) to Market Perform saying the company's "disappointing" 2017 revenue guidance suggests its pharma business is facing more headwinds than he expected. J&J guided to underlying sales growth in 2017 of 3.0%-3.5%, which is a "sharp deceleration" from 7.4% underlying growth in 2016, Biegelsen tells investors in a research note. Since the company expects its medical device and consumer businesses to accelerate in 2017, the implied growth of the pharma business in 2017 is about 2.0%-3.0%, or well below the growth in 2016 of 11.5%, the analyst notes. He points out that J&J's pharma business has been the company's key growth driver over the past few years. He keeps a $122-$124 price target range for the shares. Biegelsen downgraded Johnson & Johnson before the company's announced acquisition of Actelion (ALIOF). He wrote, though, that any deal wouldn't likely close until late 2017.
01/31/17
01/31/17
NO CHANGE

Deutsche sees label warnings as worst case for Actelion drug
After France's National Agency for the Safety of Medicines and Health Products, in a letter dated January 24, asked doctors to stop treating new patients with Actelion's (ALIOF) Uptravi as it investigates patient deaths, Deutsche Bank said it believes a label warnings for the pulmonary arterial hypertension drug is likely the worst case scenario. The firm thinks Johnson & Johnson (JNJ) likely knew of the letter before reaching an agreement to acquire Actelion. Shares of Actelion are down 4% to $65.40 in morning trading.
AMRN Amarin
$3.29

0.03 (0.92%)

10/04/16
CANT
10/04/16
INITIATION
Target $6
CANT
Buy
Amarin initiated with a Buy at Cantor
Cantor initiated Amarin with a Buy and a $6 price target.
05/12/16
05/12/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amarin (AMRN) assumed with a Buy at Jefferies by analyst Hugo Ong, who said off-label Vascepa promotion in mixed dyslipidemia may be beginning to bear fruit. 2. Theravance Biopharma (TBPH) initiated with an Outperform at Leerink with analyst Paul Matteis saying he sees a favorable risk/reward ahead of a string of clinical/commercial catalysts over the next year. 3. Graphic Packaging (GPK) initiated with a Conviction Buy at Goldman. 4. Owens-Illinois (OI) initiated with a Sell at Goldman. 5. Sonoco Products (SON) initiated with a Neutral at Goldman. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/16
SBSH
10/19/16
INITIATION
Target $5
SBSH
Buy
Citi starts Amarin with Buy rating, $5 price target
Citi analyst Joel Beatty initiated Amarin with a Buy rating and $5 price target. The biopharmaceutical company closed yesterday up 1c to $3.00. If the ongoing REDUCE-IT outcomes trial for the company's sole drug Vascepa is positive in late 2017 or early 2018, the label will be expanded to treat adults with triglycerides greater than or equal to 150, which is almost a 20 times larger market than the drug's current indication, Beatty tells investors in a research note. The analyst estimates the stock would trade up to $16 per share on news of a positive trial. In this scenario, he models Vascepa sales peaking at $2.6B in 2024.
10/19/16
10/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DuPont (DD) initiated with a Buy at Nomura. 2. Square (SQ) initiated with a Neutral at Credit Suisse. 3. GoDaddy (GDDY) initiated with a Buy at Cantor. 4. Wix.com (WIX) was initiated with a Buy at Cantor while the firm initiated Web.com (WEB) initiated with a Hold. 5. Amarin (AMRN) initiated with a Buy at Citi. The firm has a $5 price target on the stock. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ARLZ Aralez
$2.25

0.05 (2.27%)

ATRC AtriCure
$18.96

0.09 (0.48%)

03/06/17
BTIG
03/06/17
DOWNGRADE
BTIG
Neutral
AtriCure downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded AtriCure to Neutral citing the recent rally in shares, continued lack of clarity around the DEEP trial, and potentially slower enrollment than expected in CONVERGE.
08/05/16
ADAM
08/05/16
NO CHANGE
Target $21
ADAM
Buy
AtriCure weakness a buying opportunity, says Canaccord
Canaccord said the weakness in AtriCure is a buying opportunity and it has become one of their top small cap picks. The company lowered its guidance but still sees revenue growth of 15% with 72% gross margins, which should lead new investors to start positions, the firm contends. Canaccord reiterated its Buy rating and lowered its price target to $21 from $24 on AtriCure shares.
08/05/16
JMPS
08/05/16
NO CHANGE
JMPS
AtriCure should be bought on any weakness, says JMP Securities
After AtriCure reported in-line revenue and higher than expected EPS but cut its guidance, JMP Securities analyst John Gillings says the guidance was reduced due to sales force disruptions. The analyst expects the sales force to "normalize over time," and he believes that the company will be able to adjust to changes in its key end markets. Gillings trimmed his price target on the shares to $23 from $25 but recommends buying the shares on any weakness and keeps an Outperform rating.
06/30/16
06/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Canadian Pacific (CP) initiated with a Buy at Argus by analyst Stephen Biggar, who put a $155 price target on the stock. The analyst believes valuation reflects challenging conditions in the global economy and the industries Canadian Pacific serves and expects results to bottom soon. 2. Callaway Golf (ELY) initiated with an Outperform at FBR Capital and $12 price target, with analyst Susan Anderson saying the company is well positioned to benefit through a better golf market and its Topgolf stake. Roth Capital analyst Dave King re-initiated Callaway Golf with a Buy rating and $11 price target. The analyst sees further earnings improvement for the company driven by continued share gains, growth in the number of golf rounds played and a significant opportunity in balls. 3. AtriCure (ATRC) initiated with an Outperform rating and $25 target at JPM Securities, saying the company is well-positioned to "develop and penetrate several large opportunities" involving atrial fibrilation. 4. Regency Centers (REG) assumed with a Hold rating and $78 price target at Jefferies by analyst George Hoglund. Hoglund also started Weingarten Realty Investors (WRI) with a Hold rating and $40 price target, DDR Corp. (DDR) with a Hold rating and $19 price target, Retail Properties of America (RPAI) with a Hold rating and $17.50 price target, Ramco-Gershenson (RPT) with a Buy rating and $22 price target and Federal Realty (FRT) with a Hold at Jefferies and $160 price target. 5. Liberty Global (LBTYK) coverage resumed with a Buy rating and $40 price target at Evercore ISI by analyst Vijay Jayant. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AZN AstraZeneca
$30.69

0.17 (0.56%)

03/15/17
FBCO
03/15/17
NO CHANGE
Target $198
FBCO
Outperform
TESARO selloff overdone, says Credit Suisse
While Credit Suisse analyst Alethia Young expected TESARO (TSRO) stock weakness into SOLO2 data presented by AstraZeneca (AZN), she thinks the reaction was more overdone than her model would suggest around value of 2L gBRCA market share. The analyst still thinks that TESARO remains a key asset that should have much acquisition interest by global biopharma. Young reiterates an Outperform rating and $198 price target on TESARO's shares.
03/15/17
SBSH
03/15/17
NO CHANGE
Target $232
SBSH
Buy
Citi defends TESARO after selloff on AstraZeneca data
Citi analyst Robyn Karnauskas says she's defending shares of TESARO (TSRO) after data from AstraZeneca (AZN) led to a selloff. After speaking to TESARO management, Karnauskas believes that olaparib's 30.2 month is an outcome of a sensitivity analysis and not the right comparison to TESARO's niraparib's 22 months. Astra's data do not change the analyst's view that olaparib is not better versus niraparib. She reiterates a Buy rating on TESARO with a $232 price target.
03/14/17
PIPR
03/14/17
NO CHANGE
PIPR
Overweight
Piper still believes PARP inhibitors are largely similar
Piper Jaffray analyst Steven Breazzano believes AstraZeneca's (AZN) SOLO-2 results reinforce the importance of the clinical trial design rather than differences in the profile of the individual drugs. He sees the data as further supporting his view that the PARP inhibitors are largely similar. The less frequent scans, namely every 24 weeks for AstraZeneca's Lynparza versus every 12 weeks for TESARO's niraparib, played a meaningful role in the reported progression-free survival results, Breazzano tells investors in a research note. He points out that Clovis Oncology's (CLVS) trial, with results expected mid-year, scans every 12 weeks, meaning the benefit will likely be more in line with the 15 months reported by TESARO. The analyst reiterates an Overweight rating on Clovis.
03/14/17
RHCO
03/14/17
NO CHANGE
Target $221
RHCO
Buy
TESARO keeps advantage, but AstraZeneca closed gap, says SunTrust
SunTrust analyst Peter Lawson says that at first glance, AstraZeneca's (AZN) data in ovarian cancer maintenance setting with Lynparza looks "far better than expected." Lynparza showed "robust" median progression-free survival of 19.1 months and an "exceptionally high" 30.2 months when independently reviewed, versus 5.5 months with placebo control, Lawson tells investors in a research note. Even if the 30.2 month survival is discounted pending more detail, the data close the gap on TESARO (TSRO), the analyst contends. He believes, however, that TESARO's niraparib still has the advantage of a potentially broader label of platinum sensitive patients. Lawson keeps a Buy rating on TESARO with a $221 price target. The stock closed the trading day down 11% to $153.65.
BAYRY Bayer
$114.87

-0.375 (-0.33%)

12/19/16
12/19/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) and Bayer (BAYRY) were upgraded to Buy from Hold at Jefferies. 2. Costco (COST) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying she sees a "clear path" to accelerating same-store-sales growth in fiscal 2017 as gasoline price deflation headwinds abate and benefits arise from the new co-branded credit card. 3. United Technologies (UTX) upgraded to Outperform from Neutral at Credit Suisse with analyst Julian Mitchell saying he believes consensus estimates are poised to move higher after years of heavy investment spending drive an earnings recovery. 4. ASML (ASML) upgraded to Buy from Neutral at BofA/Merrill with analyst Kai Korschelt saying a recent expert's call indicates progress with Extreme Ultraviolet/EUV lightsource optics & ecosystem and sees improving volume visibility from 2018 forward. 5. Gulfport Energy (GPOR) upgraded to Buy from Neutral at Guggenheim and to Overweight from Equal Weight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/17
JPMS
01/04/17
UPGRADE
JPMS
Overweight
Bayer upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser upgraded Bayer to Overweight saying the valuation is "cheap" while the company has limited exposure to Pharma sector headwinds.
01/06/17
JPMS
01/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares are mispriced, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says Monsanto (MON) shares are mispriced and offer an attractive risk/reward proposition. A first catalyst for the shares would be regulatory agreement in the Dow Chemical (DOW)/DuPont (DD) transaction, Zekauskas tells investors in a research note. The analyst thinks a favorable resolution to the Dow/DuPont merger would be seen as improving the probability of the success of the Bayer/Monsanto transaction. He notes that Bayer has agreed to purchase Monsanto for $128 per share in cash, which represents 21% appreciation potential should the deal close by year-end. Zekauskas thinks a "reasonable floor" price for Monsanto shares, should the deal fail, is $102. He keeps an Overweight rating on the name with a $128 price target.
03/03/17
JPMS
03/03/17
NO CHANGE
Target $128
JPMS
Overweight
EU approvals of other ag deals may narrow Monsanto deal spread, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas said commentary from the CEOs of DuPont (DD) and Syngenta (SYT) and press reports from Europe suggest that their deals with Dow Chemical (DOW) and ChemChina, respectively, are likely to be approved. Approvals from Europe for those deals may "trigger a meaningful closing of the arbitrage spread" in Monsanto (MON) shares versus Bayer's (BAYRY) offer price, Zekauskas tells investors. He recommends buying Monsanto shares at current levels for this reason, adding that he believes the shares would only fall about 2.5%, or down to $112, in the event of the Bayer deal falling through. Zekauskas keeps an Overweight rating and $128 price target on Monsanto shares, which closed yesterday at just below $115 per share.
BSX Boston Scientific
$24.43

0.14 (0.58%)

02/23/17
STFL
02/23/17
NO CHANGE
STFL
Buy
Boston Scientific shares defended at Stifel
02/24/17
LEER
02/24/17
NO CHANGE
LEER
Outperform
Selloff in Boston Scientific shares 'overdone,' says Leerink
Leerink analyst Danielle Antalffy believes the selloff in Boston Scientific's shares was "overdone" and would recommend buying on weakness following the announcement of a Lotus recall in Europe and 2-quarter delay in U.S. PMA filing/approval. The analyst believes the impact from the Lotus recall is limited, and reiterates an Outperform rating on the shares.
03/08/17
SBSH
03/08/17
NO CHANGE
SBSH
Citi getting more bullish on Medtronic after electrophysiologist survey
Citi analyst Amit Hazan says his firm's U.S. electrophysiologist survey shows slightly better than expected cardiac rhythm therapies volume growth, less share loss for Medtronic (MDT) than expected and modest share gains for Boston Scientific (BSX). The survey is most positive for Medtronic relative to CRM expectations, Hazan tells investors in a research note. He notes that the company is increasingly becoming one of his favorite stocks in the group. Hazan has a Buy rating on Medtronic with a $93 price target.
02/14/17
WELS
02/14/17
NO CHANGE
WELS
Medtronic data likely to be positive, says Wells Fargo
Wells Fargo predicts that data on Medtronic's (MDT) CoreValve/Evolut R, due to be presented on March 17, will show that the device "is superior to surgical aortic valve replacement in intermediate risk patients." If the results come in as expected, the device should be approved in the U.S. by early fall, according to the firm. Wells Fargo adds that the data should also be a positive for other TAVR stocks, including Edwards Lifesciences (EW) and Boston Scientific (BSX). Wells keeps Outperform ratings on all three stocks.
BMY Bristol-Myers
$56.29

-1.02 (-1.78%)

03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
03/06/17
FBCO
03/06/17
NO CHANGE
FBCO
Near-Term acquisition of Bristol-Myers unlikely, says Credit Suisse
Credit Suisse analyst Vamil Divan says there is increasing investor focus on strategic actions and opportunities around Bristol-Myers (BMY) following the company's recent stumbles and the increased stake activist investors have taken in the stock. The analyst notes that "the big question" remains whether any of its peers may be interested in an outright acquisition, with Pfizer (PFE), Novartis (NVS) and Gilead (GILD) among the possible acquirers. While the numbers may make sense, Divan sees an acquisition in the next 9-12 months as unlikely as he needs more clarity on some of the large unknowns in the lung cancer market and macro issues such as corporate tax reform.
02/15/17
DBAB
02/15/17
NO CHANGE
DBAB
Deutsche not seeing Pfizer buying Bristol-Myers at this time
Following yesterday's speculation of a potential deal, Deutsche Bank analyst Gregg Gilbert said he would be surprised to see Pfizer (PFE) make a move on Bristol-Myers Squibb (BMY) at this stage. Such an acquisition "would represent a very large and concentrated opportunity/risk on immuno-oncology, an area fraught with near-term uncertainty," Gilbert told investors last night in a research note. He believes that if Pfizer were to use $90B for a deal, it would prefer to acquire a more diverse set of value drivers. The analyst keeps a Hold rating on Bristol and Buy rating on Pfizer. Bristol shares rose 3% yesterday to $53.71 amid speculation of a potential takeover. The conjecture had Roche (RHHBY), Novartis (NVS) and Pfizer potentially looking into a bid for Bristol.
02/01/17
GSCO
02/01/17
NO CHANGE
GSCO
Bristol-Myers estimates trimmed for Sprycel loss at Goldman
Goldman reduced Bristol-Myers earnings estimates by 4c-7c for 2017-2021 to reflect the lost of the Sprycel appeal in the EU. The firm continues to rate Bristol-Myers a Buy.
CERN Cerner
$56.61

0.26 (0.46%)

02/10/17
AVON
02/10/17
DOWNGRADE
Target $45
AVON
Market Perform
Cerner downgraded to Market Perform from Outperform at Avondale
Avondale analyst Greg Bolan downgraded Cerner to Market Perform and lowered its price target to $45 from $61 following the Q4 report and lowered CY17 guidance. Bolan said the pipeline "today" will convert to bookings in a very different way than previous years and this is clearly a result of less software-laden demands by IDNs. Bolan said revenue guidance has grinded lower over the past several years and no longer feels comfortable with predictability of his estimates.
02/10/17
02/10/17
DOWNGRADE

Perform
Cerner downgraded to Perform at Oppenheimer
As previously reported, Oppenheimer analyst Mohan Naidu downgraded Cerner to Perform from Outperform as he starts to see limited upside to growth and margin expansion potential in the near-term. Flat 2016 bookings, limited traction with large services deal flow and lack of incentives for hospitals to commit on large projects as they await the new administration's direction makes the analyst believe that earnings growth will be muted in the near-term.
02/24/17
SBSH
02/24/17
DOWNGRADE
SBSH
Neutral
Cerner downgraded to Neutral from Buy at Citi
02/24/17
SBSH
02/24/17
DOWNGRADE
Target $60
SBSH
Neutral
Cerner downgraded to Neutral on valuation at Citi
Citi analyst Garen Sarafian downgraded Cerner to Neutral from Buy citing valuation with the stock up 8% since the post-Q4 earnings low. The analyst feels the shares are near fair value and keeps a $60 price target for the name.
CYTK Cytokinetics
$12.40

-0.95 (-7.12%)

03/08/17
03/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Skyworks (SWKS) initiated at Wells Fargo. 2. Jagged Peak Energy (JAG) initiated with a Sector Perform at Scotia Howard Weil. 3. Splunk (SPLK) initiated with a Buy at Rosenblatt. 4. Laureate Education (LAUR) initiated with an Overweight at JPMorgan. 5. Cytokinetics (CYTK) initiated with a Buy at Rodman & Renshaw. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/08/17
RODM
03/08/17
INITIATION
Target $25
RODM
Buy
Cytokinetics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Cytokinetics with a Buy rating and $25 price target. The analyst views the stock as a core long-term holding for investors.
02/06/17
02/06/17
UPGRADE
Target $22

Strong Buy
Cytokinetics upgraded to Strong Buy at Needham
As previously reported, Needham analyst Chad Messer upgraded Cytokinetics to Strong Buy from Buy ahead of pivotal Tirsemtiv data and multiple other drivers. The analyst also raised his price target to $22 from $17.
02/06/17
NEED
02/06/17
UPGRADE
NEED
Strong Buy
Cytokinetics upgraded to Strong Buy from Buy at Needham
EW Edwards Lifesciences
$94.40

1.45 (1.56%)

03/08/17
RBCM
03/08/17
NO CHANGE
RBCM
Edwards should be bought on any post-trial weakness, says RBC Capital
RBC Capital analyst Glenn Novarro estimates that there is a 70% chance of interim data showing that Medtronic's (MDT) CoreValve and CoreValve Evolut R are non-inferior to surgery and a 30% chance of the devices being shown to be superior to surgery. The analyst thinks that Edwards Lifesciences' stock will fall around 5% if the devices are shown to be non-inferior, and he believes that the stock will rise 5%-10% if it shown to be superior. However, the analyst believes that even a finding of non-inferiority will increase TAVR devices' market share, and he recommends buying Edwards on any pullback.
02/21/17
ADAM
02/21/17
NO CHANGE
Target $140
ADAM
Buy
Edwards Lifesciences should react positively to TMVR news, says Canaccord
Canaccord analyst Jason Mills believes Edwards Lifesciences shares should react positively to the news released in its 10K that it would resume clinical activity with its EW-CardiAQ TMVR platform following completion of validation testing. This comes on the heels of management voluntarily pausing the trials to perform design testing on a specific valve function. Mills recommends investors be more aggressive near-term as the restart of patient screening should help ally concerns that a material valve change may have been warranted. Mills reiterated his Buy rating and $140 price target on Edwards shares.
02/02/17
LEER
02/02/17
DOWNGRADE
Target $105
LEER
Market Perform
Edwards Lifesciences downgraded to Market Perform from Outperform at Leerink
Leerink analyst Danielle Antalffy downgraded Edwards Lifesciences to Market Perform from Outperform saying long-term market opportunity remains intact but near-term upside is limited. The analyst believes TAVR represents one of the more exciting new MedTech markets, but the ramp in less sick patient populations may progress at a slower pace than elevated investor expectations. Further, Antalffy believes upside to shares will be limited from here, as "beat and raise" will be more difficult in light of a potentially slower than initially expected intermediate risk ramp and increasing competition. She also lowered her price target on the shares to $105 from $110.
GILD Gilead
$69.06

0.52 (0.76%)

02/24/17
LEER
02/24/17
NO CHANGE
LEER
Merck write-down suggests 'rest of Idenix' is now 'very small,' says Leerink
Leerink analyst Geoffrey Porges notes that Merck (MRK) announced that it is taking a $2.9B impairment charge against the value of uprifosbuvir, or MK3682, which is the most important of the Hepatitis C nucleotide polymerase inhibitors it acquired from Idenix. The analyst believes this write-down suggests that the remaining value of the "rest of Idenix" is now very small. In addition to the delay for Merck's triple regimen, this impairment has "significant competitive implications" for Gilead (GILD) and AbbVie (ABBV), which are the most likely remaining participants in the HCV market, he adds.
03/09/17
UBSW
03/09/17
DOWNGRADE
Target $72
UBSW
Neutral
Gilead transferred with a Neutral from Buy at UBS
UBS downgraded Gilead Sciences to Neutral after transferring coverage to Carter Gould. The company's hepatitis C sales have declined steadily since 2015 on decreased patient volume and pricing pressure, Gould told investors last night in a research note. The analyst believes Gilead's HCV sales need to stabilize before the stock moves higher. He cut his firm's price target for the shares to $72 from $118.
03/13/17
FBCO
03/13/17
NO CHANGE
Target $174
FBCO
Outperform
Incyte price target raised to $174 from $136 at Credit Suisse
Credit Suisse analyst Kennen MacKay raised his price target for Incyte (INCY) to $174 upon shifting to an M&A discounted cash flow net present value methodology. Incyte rallied late in the day on Friday amid speculation of a takeover by Gilead Sciences (GILD). Incyte could provide an attractive entry into immuno-oncology for an acquirer, MacKay tells investors in a research note. The company's epacadostat could be a "scarce immuno-oncology backbone blockbuster," the analyst contends. He anticipates "significant interest" in Incyte for this reason. MacKay keeps an Outperform rating on the shares.
KRO Kronos Worldwide
$15.44

0.14 (0.92%)

MCK McKesson
$147.93

-0.9 (-0.60%)

01/20/17
LEER
01/20/17
NO CHANGE
Target $155
LEER
Market Perform
McKesson price target lowered to $155 from $160 at Leerink
Leerink analyst David Larsen lowered his price target for McKesson to $155 from $160 as he believes volume and pricing trends remain challenges, the FDA will likely continue with a steady stream of generic approvals which will put pressure on pricing, Trump may be more aggressive about price controls than expected, and as the company's competitive positioning in the market has weakened due to purchasing scale. The analyst reiterates a Market Perform rating on the shares.
01/18/17
01/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. TransUnion (TRU) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Toni Kaplan saying she views TransUnion's valuation as attractive and believes organic growth estimates are achievable. 2. Nordstrom (JWN) and Burlington Stores (BURL) were upgraded to Outperform from Neutral at Credit Suisse. 3. Scorpio Bulkers (SALT) upgraded to Buy from Hold at Evercore ISI with analyst Jonathan Chappell saying the company took the painful steps of raising equity on a dilutive basis, enabling it to refinance with its banks and provide the best medium-term liquidity runway in the group. 4. McKesson (MCK) upgraded to Outperform from Market Perform at Avondale. 5. Deckers Brands (DECK) upgraded to Buy from Neutral at Buckingham with analyst Scott Krasik taking a more positive view on the recently completed holiday season and sales and margin expansion opportunities for the UGG brand through fiscal 2020, following favorable channel checks. He believes increased diversification with the UGG brand, more predictable product costs and operating expenses, and accelerating free cash flow will lead to operating margin back to a low to mid-teens rate by FY20. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/17
AVON
01/17/17
UPGRADE
AVON
Outperform
McKesson upgraded to Outperform from Market Perform at Avondale
01/05/17
JPMS
01/05/17
DOWNGRADE
Target $169
JPMS
Neutral
McKesson downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Lisa Gill downgraded McKesson to Neutral citing her cautious near-term view on the broader pharmaceutical distribution sector. The analyst sees uncertainties around branded drug price inflation, generic deflation and the overall competitive environment. She lowered her price target for the shares to $169 from $171.
MDT Medtronic
$82.23

0.4 (0.49%)

02/23/17
LEER
02/23/17
NO CHANGE
Target $85
LEER
Market Perform
Medtronic price target raised to $85 from $80 at Leerink
Leerink analyst Danielle Antalffy raised her price target for Medtronic to $85 from $80 after the company delivered what he believes was an "encouraging rebound" quarter after an unexpected Q2 miss. While the analyst remains cautious on the company's ability to manage through what could be meaningful top-line headwinds in Q4 and FY18 in order to deliver a targeted mid-single-digit sales growth, it does seem that the diversified business model gives it a cushion with which to offset underperforming business segments with stronger/faster growth elsewhere. He reiterates a Market Perform rating on the shares.
03/14/17
RBCM
03/14/17
NO CHANGE
RBCM
Medtronic pump delay a negative for United Therapeutics, says RBC Capital
After the FDA posted on its website that Medtronic (MDT) is recalling the SynchroMed Implantable Infusion Pumps because of a software problem, RBC Capital said this new recall may impact the timeline for United Therapeutics (UTHR) implantable pump. In March of last year, United Therapeutics said that Medtronic and the company were assessing a U.S. Food and Drug Administration response letter to Medtronic's premarket approval application, PMA, for the Remodulin Implantable System and measures to address the agency's concerns.
PFE Pfizer
$34.32

-0.11 (-0.32%)

02/21/17
FBCO
02/21/17
NO CHANGE
Target $42
FBCO
Outperform
Glatopa 40mg delay a 'surprising positive' for Teva, says Credit Suisse
Credit Suisse analyst Vamil Divan says the news that Pfizer (PFE) has received a warning letter at a plant that is involved with the production of Sandoz and Momenta's (MNTA) Glatopa products is a surprising positive for Teva (TEVA), noting that he has viewed Sandoz and Momenta as most likely to have the first generic Copaxone 40mg on the market. The analyst reiterated an Outperform rating on Teva's stock, and raised his price target on the shares to $42 from $41.
02/21/17
LEER
02/21/17
NO CHANGE
LEER
Outperform
Warning letter raises concerns on Momenta Copaxone catalyst, says Leerink
Leerink analyst Jason Gerberry notes that Momenta (MNTA) disclosed that its generic Copaxone 40mg ANDA will be delayed by an FDA warning letter at its fill-finish manufacturing partner, Pfizer (PFE). The analyst says that while a short delay to Momenta/Novartis' (NVS) g-Copaxone 40mg is not reason for concern, longer delays could diminish the market opportunity as there are four other generic challengers, but none have been able to prove bioequivalence to Teva's (TEVA) lower strength. He reiterates an Outperform rating on Momenta's shares.
03/14/17
LEER
03/14/17
NO CHANGE
LEER
Monitoring requests put Novartis Kisqali at marketing disadvantage, says Leerink
Leerink analyst Seamus Fernandez notes that Novartis (NVS) announced the FDA approval of its CDK4/6 inhibitor Kisqali in combination with an aromatase inhibitor for the first-line treatment of post-menopausal women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. The analyst says that the label contains warnings for QT prolongation as well as liver toxicity, both of which necessitate frequent monitoring. Although Kisqali appears to have similar efficacy to Pfizer (PFE) approved Ibrance, the latter's label does not include these warnings or monitoring requirements, he points out, adding that he continues to see Ibrance maintaining long-term market dominance in the CDK4/6 class.
STJ Acquired by ABT

08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
WTKWY Wolters Kluwer
$41.30

0.41 (1.00%)

03/10/17
GSCO
03/10/17
UPGRADE
GSCO
Neutral
Wolters Kluwer upgraded to Neutral from Sell at Goldman

TODAY'S FREE FLY STORIES

02:35
11/23/17
11/23
02:35
11/23/17
02:35
General news
FX Update: The dollar has remained on a downward path »

FX Update: The dollar…

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$180.87

-0.99 (-0.54%)

17:47
11/22/17
11/22
17:47
11/22/17
17:47
Periodicals
Facebook tool to show users which content was Russian propaganda, says Bloomberg »

Facebook will add a tool…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$51.01

0.79 (1.57%)

17:24
11/22/17
11/22
17:24
11/22/17
17:24
Periodicals
CSX to charge more fees on customers that disregard shipping rules, Reuters says »

Starting on January 1st,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AYTU

Aytu BioScience

$3.03

0.4301 (16.54%)

17:10
11/22/17
11/22
17:10
11/22/17
17:10
Syndicate
Breaking Syndicate news story on Aytu BioScience »

Aytu BioScience files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPIX

ESSA Pharma

$0.27

0.0059 (2.27%)

17:09
11/22/17
11/22
17:09
11/22/17
17:09
Hot Stocks
ESSA Pharma to begin trading on TSX Venture Exchange »

ESSA Pharma is listing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRDN

Meridian Waste Solutions

$1.69

0.0101 (0.60%)

16:55
11/22/17
11/22
16:55
11/22/17
16:55
Syndicate
Breaking Syndicate news story on Meridian Waste Solutions »

Meridian Waste Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

$161.62

-0.67 (-0.41%)

16:50
11/22/17
11/22
16:50
11/22/17
16:50
Syndicate
Breaking Syndicate news story on Air Products »

Air Products files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOOT

Boot Barn

$13.49

-0.23 (-1.68%)

16:49
11/22/17
11/22
16:49
11/22/17
16:49
Syndicate
Breaking Syndicate news story on Boot Barn »

Boot Barn files $300M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$17.50

0.88 (5.29%)

, BCEI

Bonanza Creek

$32.14

0.46 (1.45%)

16:44
11/22/17
11/22
16:44
11/22/17
16:44
Hot Stocks
Icahn reports 13.51% stake in SandRidge Energy, intends to vote against Bonanza »

Icahn has read Fir Tree…

SD

SandRidge Energy

$17.50

0.88 (5.29%)

BCEI

Bonanza Creek

$32.14

0.46 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$17.50

0.88 (5.29%)

16:35
11/22/17
11/22
16:35
11/22/17
16:35
Hot Stocks
Icahn reports 13.51% stake in SandRidge Energy, intends to vote against Bonanza »

Icahn agrees with Fir…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$28.43

0.32 (1.14%)

, AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

16:32
11/22/17
11/22
16:32
11/22/17
16:32
Hot Stocks
Symantec selects Amazon Web Services to deliver cloud security »

Amazon Web Services, an…

SYMC

Symantec

$28.43

0.32 (1.14%)

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

16:30
11/22/17
11/22
16:30
11/22/17
16:30
Options
Preliminary option volume of 13.6M today »

Preliminary option volume…

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

16:26
11/22/17
11/22
16:26
11/22/17
16:26
Hot Stocks
Amazon Web Services announces Amazon ML Solutions Lab program »

Amazon Web Services, Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

NRIM

Northrim BanCorp

$34.75

-0.25 (-0.71%)

16:22
11/22/17
11/22
16:22
11/22/17
16:22
Hot Stocks
Northrim BanCorp announces CFO transition »

Northrim BanCorp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

, CERN

Cerner

$70.03

3.35 (5.02%)

16:21
11/22/17
11/22
16:21
11/22/17
16:21
General news
On The Fly: Top stock stories for Wednesday »

Stocks opened in positive…

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

CERN

Cerner

$70.03

3.35 (5.02%)

HPE

HP Enterprise

$13.10

-1.02 (-7.22%)

HPQ

HP Inc.

$21.34

-1.12 (-4.99%)

DE

Deere

$145.25

6.02 (4.32%)

ROK

Rockwell Automation

$191.02

-2 (-1.04%)

EMR

Emerson

$61.88

1.53 (2.54%)

AKZOY

AkzoNobel

$31.04

0.475 (1.55%)

AXTA

Axalta Coating

$35.50

1.63 (4.81%)

GME

GameStop

$17.37

0.64 (3.83%)

GES

Guess

$15.62

-2.33 (-12.98%)

IRBT

iRobot

$68.50

-4.57 (-6.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 11

    Dec

  • 18

    Mar

CHMI

Cherry Hill Mortgage

$18.51

0.06 (0.33%)

16:21
11/22/17
11/22
16:21
11/22/17
16:21
Syndicate
Breaking Syndicate news story on Cherry Hill Mortgage »

Cherry Hill Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$49.75

-0.23 (-0.46%)

16:20
11/22/17
11/22
16:20
11/22/17
16:20
Hot Stocks
Nektar names new CRDO, CMO and CSO »

Nektar announced several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
11/22/17
11/22
16:20
11/22/17
16:20
Options
Closing CBOE SPX and VIX Index summary for November 22nd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VGZ

Vista Gold

$0.68

0.0069 (1.03%)

16:18
11/22/17
11/22
16:18
11/22/17
16:18
Syndicate
Vista Gold enters $10M ATM agreement with H.C. Wainwright & Co. »

Vista Gold announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPX

GP Strategies

$23.50

-0.2 (-0.84%)

16:17
11/22/17
11/22
16:17
11/22/17
16:17
Hot Stocks
GP Strategies announces $10M share repurchase increase »

GP Strategies Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

$NSD

NASDAQ Market Internals

16:17
11/22/17
11/22
16:17
11/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.